234 related articles for article (PubMed ID: 29757042)
1. Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab.
Kim BR; Yang S; Choi CW; Youn SW
J Dermatolog Treat; 2019 Mar; 30(2):123-128. PubMed ID: 29757042
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
Rigopoulos D; Gregoriou S; Makris M; Ioannides D
Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
Patsatsi A; Kyriakou A; Sotiriadis D
J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of psoriatic crumbly nails with ustekinumab.
Galluzzo M; D'Adamio S; Chimenti MS; Teoli M; Bianchi L; Talamonti M
Dermatol Ther; 2019 May; 32(3):e12914. PubMed ID: 30968520
[TBL] [Abstract][Full Text] [Related]
6. Fingernail psoriasis reconsidered: a case-control study.
van der Velden HM; Klaassen KM; van de Kerkhof PC; Pasch MC
J Am Acad Dermatol; 2013 Aug; 69(2):245-52. PubMed ID: 23541759
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
Wasel N; Thaçi D; French LE; Conrad C; Dutronc Y; Gallo G; Berggren L; Lacour JP
Dermatol Ther (Heidelb); 2020 Aug; 10(4):663-670. PubMed ID: 32415575
[TBL] [Abstract][Full Text] [Related]
8. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
[TBL] [Abstract][Full Text] [Related]
10. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
Jemec GB; Ibler KS
J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
12. Dermoscopic features of nail psoriasis treated with biologics.
Hashimoto Y; Uyama M; Takada Y; Yoshida K; Ishiko A
J Dermatol; 2017 May; 44(5):538-541. PubMed ID: 28150346
[TBL] [Abstract][Full Text] [Related]
13. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis.
Bardazzi F; Antonucci VA; Tengattini V; Odorici G; Balestri R; Patrizi A
J Dtsch Dermatol Ges; 2013 Nov; 11(11):1065-70. PubMed ID: 24119121
[TBL] [Abstract][Full Text] [Related]
14. Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: A prospective cohort study.
Muñoz-Santos C; Sola-Ortigosa J; Vidal D; Guilabert A
J Dermatol; 2021 Oct; 48(10):1593-1596. PubMed ID: 34390034
[TBL] [Abstract][Full Text] [Related]
15. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
[TBL] [Abstract][Full Text] [Related]
19. Treatment of nail psoriasis with intralesional triamcinolone acetonide using a needle-free jet injector: a prospective trial.
Nantel-Battista M; Richer V; Marcil I; Benohanian A
J Cutan Med Surg; 2014; 18(1):38-42. PubMed ID: 24377472
[TBL] [Abstract][Full Text] [Related]
20. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
Rigopoulos D; Gregoriou S; Daniel Iii CR; Belyayeva H; Larios G; Verra P; Stamou C; Kontochristopoulos G; Avgerinou G; Katsambas A
Dermatology; 2009; 218(4):338-41. PubMed ID: 19212110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
